ERBB2 and lymphoproliferative syndrome: Phenethyl isothiocyanate (DB12695), although clinically studied in prevention and the treatment of leukemia, lung cancer, tobacco use and lymphoproliferative disorders, was shown to hamper the growth and progression of in vitro HER2-positive breast and ovarian carcinoma [58].